Clinical cell processing news – part 3, 2013

by Alexey Bersenev on May 8, 2013 · 0 comments

in cell product, clinical lab

Post to Twitter Send Gmail Post to LinkedIn

Clinical Cell Processing News series overviews new protocols, products and techniques for clinical-grade cell processing and manufacturing. Cell processing devices, cultureware, bioreactors, GMP-grade reagents, cell separation techniques. Follow us!

1. Validation of dry-thawing device for hematopoietic cell products (Transfusion):

Progenitor cell viability and function are preserved with this dry-thawing system. The time to hematopoietic engraftment of patients after transplantation is comparable to those infused with progenitor cells thawed with the water bath technique.

2. Validation of automated system for cord blood processing SynGenX™-1000 (Cytotherapy):

The SynGenX-1000 system consistently yields TNC, MNC & CD34+ recovery greater than 90% from cord blood volumes of 72-146 mL. The results demonstrate that the SynGenX-1000 system can achieve automated volume reduction of blood with a high efficiency of TNC & MNC recovery without the use of HES.

3. Characterization of ex vivo expanded human placenta-derived NK cell product (Front Immunol):

Here we define methods to efficiently generate NK cells from donor-matched, full-term human placenta perfusate (termed Human Placenta-Derived Stem Cell, HPDSC) and UCB.

4. Mononuclear cell isolation from cord blood – comparison of automated Sepax2 versus manual ficoll methods (Cytotherapy):

The Sepax MNC enrichment method offers an advantage over the manual method in terms of being a closed system and better cell recoveries.

5. Evaluation of BD Mosaic™ Mesenchymal Stem Cell Serum-free medium for large-scale expansion (J Tiss Eng Regen Med):

Our results suggest that BD-SFM supports large-scale expansion of BM-MSCs for therapeutic use.

6. Validation of Fenwal cell washing device using spinning membrane filtration (Cytotherapy):

The use of spinning membrane filtration for cell washing protocols generates a platelet-reduced WBC product with good viability and supernatant removal, while avoiding unnecessary pelletization.

7. Validation of automatic cell counting device Fast Read 102® in GMP facility (J Transl Med):

Under our standard method procedures, this assay may thus be considered a good quality control method for the cell count as a batch release quality control test. Moreover, the Fast Read 102® chamber is a plastic, disposable device that allows a number of samples to be counted in the same chamber.

8. Comparison different methods of freezing cord blood units (Transfusion):

Neither the cryopreservation procedure nor the freezing of isolated HSCs affected product quality, which may indicate that various freezing methods can be used for cell banking provided the they follow recommendations of good manufacturing practice and Directive 2004/33/EC.

9. Evaluation of pooled platelet lysate versus serum in clinical-grade expansion of adipose-derived stem cells (Cytotherapy):

We observed that the use of pHPL as a growth supplement for ASCs facilitated a significantly higher proliferation rate compared with FBS without compromising genomic stability or differentiation capacity.

{ 0 comments… add one now }

Leave a Comment

Previous post:

Next post: